Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Arecor Therapeutics's Debt-to-EBITDA or its related term are showing as below:
STU:6UI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.61 Med: -0.04 Max: 0.08
Current: 0.08
During the past 9 years, the highest Debt-to-EBITDA Ratio of Arecor Therapeutics was 0.08. The lowest was -0.61. And the median was -0.04.
STU:6UI's Debt-to-EBITDA is ranked better than 85.76% of 295
companies
in the Biotechnology industry
Industry Median: 1.14
vs STU:6UI: 0.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Arecor Therapeutics Debt-to-EBITDA Related Terms
Arecor Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Arecor Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6UI vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Arecor Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Arecor Therapeutics (STU:6UI) has a Debt-to-EBITDA of 0.01 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Arecor Therapeutics. According to the industry distribution chart, Arecor Therapeutics ranks #42 out of 295 companies in the Biotechnology industry, placing it in the top 14.2%.
Is Arecor Therapeutics' Debt-to-EBITDA too high?
Arecor Therapeutics' current Debt-to-EBITDA is 0.01. The Biotechnology industry median Debt-to-EBITDA is 1.14. Arecor Therapeutics' value of 0.01 is 99.1% below this industry median. Based on the distribution chart, Arecor Therapeutics ranks #42 out of 295 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arecor Therapeutics has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #42 out of 295 companies for Debt-to-EBITDA. This places Arecor Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.14. Arecor Therapeutics' value of 0.01 is 99.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 295 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arecor Therapeutics's current Debt-to-EBITDA of 0.01 is 99.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Arecor Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arecor Therapeutics's current Debt-to-EBITDA is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (STU:6UI) has a current Debt-to-EBITDA of 0.01. The stock's GF Value™ is €0.49, compared to a current price of €0.69 — trading 39.8% above its estimated fair value. The current Debt-to-EBITDA is 0.01 and 99.1% below the Biotechnology industry median of 1.14. Arecor Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Arecor Therapeutics (STU:6UI), the current Debt-to-EBITDA is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.
Key valuation signals for STU:6UI:
Debt-to-EBITDA: 0.01
GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
Industry Position: 99.1% below the Biotechnology median (#42 of 295)
No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
39GF Score
Get the complete analysis for STU:6UI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6UI has been successfully added to your 
